Skip to main content
Top
Published in: Journal of Community Health 3/2019

01-06-2019 | Original Paper

Aspirin Use for Cardiovascular Disease Prevention in an African American Population: Prevalence and Associations with Health Behavior Beliefs

Authors: Jeremy R. Van’t Hof, Sue Duval, Jeffrey R. Misialek, Niki C. Oldenburg, Clarence Jones, Milton Eder, Russell V. Luepker

Published in: Journal of Community Health | Issue 3/2019

Login to get access

Abstract

Cardiovascular disease (CVD) is a leading cause of morbidity and mortality in the United States, disproportionately affecting African Americans. Aspirin is an effective, low cost option to reduce cardiovascular events. This study sought to describe the use of aspirin for CVD prevention in African Americans and evaluate associations with demographics, cardiovascular risk factors and health behaviors and beliefs. A total of 684 African Americans adults ages 45–79 years completed surveys and were included in this analysis. Proportions of aspirin use were stratified by primary and secondary prevention and by number of CVD risk factors in the primary prevention population. Logistic regression was used to evaluate associations with aspirin use. Secondary prevention aspirin use was 62%. Primary prevention aspirin use was 32% overall and increased to 54% in those with > 2 CVD risk factors. A history of diabetes [adjusted odds ratio (aOR) 3.42, 95% CI 2.18–5.35] and hypertension (aOR 2.25, 95% CI 1.39–3.65) were strongly associated with primary prevention aspirin use, but a conversation with a health care provider was even stronger (aOR 6.41, 95% CI 4.07–10.08). Participants who answered positively to statements about people similar to them taking aspirin or that close contacts think they should take aspirin, were much more likely to take aspirin (aOR 4.80; 95% CI 2.58–8.93 and aOR 7.45; 95% CI 4.70–11.79 respectively). These findings support a hypothesis that aspirin use may increase by encouraging conversations with health care providers and creating a supportive social environment for aspirin use. Further studies need to be done to test this hypothesis.
Appendix
Available only for authorised users
Literature
1.
go back to reference Benjamin, E. J., Virani, S. S., Callaway, C. W., Chamberlain, A. M., Chang, A. R., Cheng, S., et al. (2018). Heart disease and stroke statistics-2018 update: A report from the American Heart Association. Circulation, 137(12), e67–e492.CrossRefPubMed Benjamin, E. J., Virani, S. S., Callaway, C. W., Chamberlain, A. M., Chang, A. R., Cheng, S., et al. (2018). Heart disease and stroke statistics-2018 update: A report from the American Heart Association. Circulation, 137(12), e67–e492.CrossRefPubMed
2.
go back to reference Mensah, G. A., Mokdad, A. H., Ford, E. S., Greenlund, K. J., & Croft, J. B. (2005). State of disparities in cardiovascular health in the United States. Circulation, 111(10), 1233–1241.CrossRefPubMed Mensah, G. A., Mokdad, A. H., Ford, E. S., Greenlund, K. J., & Croft, J. B. (2005). State of disparities in cardiovascular health in the United States. Circulation, 111(10), 1233–1241.CrossRefPubMed
3.
go back to reference Sidney, S., Quesenberry, C. P., Jaffe, M. G., Sorel, M., Nguyen-Huynh, M. N., Kushi, L. H., et al. (2016). Recent trends in cardiovascular mortality in the United States and public health goals. JAMA Cardiology, 1(5), 594–599.CrossRefPubMed Sidney, S., Quesenberry, C. P., Jaffe, M. G., Sorel, M., Nguyen-Huynh, M. N., Kushi, L. H., et al. (2016). Recent trends in cardiovascular mortality in the United States and public health goals. JAMA Cardiology, 1(5), 594–599.CrossRefPubMed
4.
go back to reference Baigent, C., Blackwell, L., Collins, R., Emberson, J., Godwin, J., Peto, R., et al. (2009). Aspirin in the primary and secondary prevention of vascular disease: Collaborative meta-analysis of individual participant data from randomised trials. Lancet, 373(9678), 1849–1860.CrossRefPubMed Baigent, C., Blackwell, L., Collins, R., Emberson, J., Godwin, J., Peto, R., et al. (2009). Aspirin in the primary and secondary prevention of vascular disease: Collaborative meta-analysis of individual participant data from randomised trials. Lancet, 373(9678), 1849–1860.CrossRefPubMed
5.
go back to reference Rothwell, P. M., Algra, A., Chen, Z., Diener, H. C., Norrving, B., & Mehta, Z. (2016). Effects of aspirin on risk and severity of early recurrent stroke after transient ischaemic attack and ischaemic stroke: Time-course analysis of randomised trials. Lancet, 388(10042), 365–375.CrossRefPubMedPubMedCentral Rothwell, P. M., Algra, A., Chen, Z., Diener, H. C., Norrving, B., & Mehta, Z. (2016). Effects of aspirin on risk and severity of early recurrent stroke after transient ischaemic attack and ischaemic stroke: Time-course analysis of randomised trials. Lancet, 388(10042), 365–375.CrossRefPubMedPubMedCentral
6.
go back to reference Luepker, R. V., Steffen, L. M., Duval, S., Zantek, N. D., Zhou, X., & Hirsch, A. T. (2015). Population trends in aspirin use for cardiovascular disease prevention 1980–2009: The Minnesota Heart Survey. Journal of the American Heart Association, 4(12), e002320.CrossRefPubMedPubMedCentral Luepker, R. V., Steffen, L. M., Duval, S., Zantek, N. D., Zhou, X., & Hirsch, A. T. (2015). Population trends in aspirin use for cardiovascular disease prevention 1980–2009: The Minnesota Heart Survey. Journal of the American Heart Association, 4(12), e002320.CrossRefPubMedPubMedCentral
7.
go back to reference Steering Committee of the Physicians’ Health Study Research Group*. (1989). Final report on the aspirin component of the ongoing Physicians’ Health Study. New England Journal of Medicine, 321(3), 129–135.CrossRef Steering Committee of the Physicians’ Health Study Research Group*. (1989). Final report on the aspirin component of the ongoing Physicians’ Health Study. New England Journal of Medicine, 321(3), 129–135.CrossRef
8.
go back to reference Hansson, L., Zanchetti, A., Carruthers, S. G., Dahlöf, B., Elmfeldt, D., Julius, S., et al. (1998). Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet, 351(9118), 1755–1762.CrossRefPubMed Hansson, L., Zanchetti, A., Carruthers, S. G., Dahlöf, B., Elmfeldt, D., Julius, S., et al. (1998). Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet, 351(9118), 1755–1762.CrossRefPubMed
9.
go back to reference Medical Research Council’s General Practice Research Framework. (1998). Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. Lancet, 351(9098), 233–241.CrossRef Medical Research Council’s General Practice Research Framework. (1998). Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. Lancet, 351(9098), 233–241.CrossRef
10.
go back to reference Ridker, P. M., Cook, N. R., Lee, I. M., Gordon, D., Gaziano, J. M., Manson, J. E., et al. (2005). A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. New England Journal of Medicine, 352(13), 1293–1304.CrossRefPubMed Ridker, P. M., Cook, N. R., Lee, I. M., Gordon, D., Gaziano, J. M., Manson, J. E., et al. (2005). A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. New England Journal of Medicine, 352(13), 1293–1304.CrossRefPubMed
11.
go back to reference Ikeda, Y., Shimada, K., Teramoto, T., Uchiyama, S., Yamazaki, T., Oikawa, S., et al. (2014). Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: A randomized clinical trial. JAMA, 312(23), 2510–2520.CrossRefPubMed Ikeda, Y., Shimada, K., Teramoto, T., Uchiyama, S., Yamazaki, T., Oikawa, S., et al. (2014). Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: A randomized clinical trial. JAMA, 312(23), 2510–2520.CrossRefPubMed
12.
go back to reference ASCEND Study Collaborative Group. (2018). Effects of aspirin for primary prevention in persons with diabetes mellitus. New England Journal of Medicine, 379(16), 1529–1539.CrossRef ASCEND Study Collaborative Group. (2018). Effects of aspirin for primary prevention in persons with diabetes mellitus. New England Journal of Medicine, 379(16), 1529–1539.CrossRef
13.
go back to reference Gaziano, J. M., Brotons, C., Coppolecchia, R., Cricelli, C., Darius, H., Gorelick, P. B., et al. (2018). Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): A randomised, double-blind, placebo-controlled trial. Lancet, 392(10152), 1036–1046.CrossRefPubMedPubMedCentral Gaziano, J. M., Brotons, C., Coppolecchia, R., Cricelli, C., Darius, H., Gorelick, P. B., et al. (2018). Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): A randomised, double-blind, placebo-controlled trial. Lancet, 392(10152), 1036–1046.CrossRefPubMedPubMedCentral
14.
go back to reference Calonge, N., Petitti, D. B., DeWitt, T. G., Gordis, L., Gregory, K. D., Harris, R., et al. (2009). Aspirin for the prevention of cardiovascular disease: US Preventive Services Task Force recommendation statement. Annals of Internal Medicine, 150(6), 396–404.CrossRef Calonge, N., Petitti, D. B., DeWitt, T. G., Gordis, L., Gregory, K. D., Harris, R., et al. (2009). Aspirin for the prevention of cardiovascular disease: US Preventive Services Task Force recommendation statement. Annals of Internal Medicine, 150(6), 396–404.CrossRef
15.
go back to reference Van’t Hof, J. R., Duval, S., Walts, A., Kopecky, S. L., Luepker, R. V., & Hirsch, A. T. (2017). Contemporary primary prevention aspirin use by cardiovascular disease risk: Impact of US Preventive Services Task Force Recommendations, 2007–2015: A Serial, Cross-sectional Study. Journal of the American Heart Association, 6(10), e006328. Van’t Hof, J. R., Duval, S., Walts, A., Kopecky, S. L., Luepker, R. V., & Hirsch, A. T. (2017). Contemporary primary prevention aspirin use by cardiovascular disease risk: Impact of US Preventive Services Task Force Recommendations, 2007–2015: A Serial, Cross-sectional Study. Journal of the American Heart Association, 6(10), e006328.
16.
go back to reference Shahar, E., Folsom, A. R., Romm, F. J., Bisgard, K. M., Metcalf, P. A., Crum, L., et al. (1996). Patterns of aspirin use in middle-aged adults: The Atherosclerosis Risk in Communities (ARIC) Study. American Heart Journal, 131(5), 915–922.CrossRefPubMed Shahar, E., Folsom, A. R., Romm, F. J., Bisgard, K. M., Metcalf, P. A., Crum, L., et al. (1996). Patterns of aspirin use in middle-aged adults: The Atherosclerosis Risk in Communities (ARIC) Study. American Heart Journal, 131(5), 915–922.CrossRefPubMed
17.
go back to reference Rodondi, N., Vittinghoff, E., Cornuz, J., Butler, J., Ding, J., Satterfield, S., et al. (2005). Aspirin use for the primary prevention of coronary heart disease in older adults. The American Journal of Medicine, 118(11), 1281–1288.CrossRef Rodondi, N., Vittinghoff, E., Cornuz, J., Butler, J., Ding, J., Satterfield, S., et al. (2005). Aspirin use for the primary prevention of coronary heart disease in older adults. The American Journal of Medicine, 118(11), 1281–1288.CrossRef
18.
go back to reference Glasser, S. P., Cushman, M., Prineas, R., Kleindorfer, D., Prince, V., You, Z., et al. (2008). Does differential prophylactic aspirin use contribute to racial and geographic disparities in stroke and coronary heart disease (CHD)? Preventive Medicine, 47(2), 161–166.CrossRefPubMedPubMedCentral Glasser, S. P., Cushman, M., Prineas, R., Kleindorfer, D., Prince, V., You, Z., et al. (2008). Does differential prophylactic aspirin use contribute to racial and geographic disparities in stroke and coronary heart disease (CHD)? Preventive Medicine, 47(2), 161–166.CrossRefPubMedPubMedCentral
19.
go back to reference Sanchez, D. R., Roux, A. V. D., Michos, E. D., Blumenthal, R. S., Schreiner, P. J., Burke, G. L., & Watson, K. (2011). Comparison of the racial/ethnic prevalence of regular aspirin use for the primary prevention of coronary heart disease from the multi-ethnic study of atherosclerosis. The American Journal of Cardiology, 107(1), 41–46.CrossRefPubMedPubMedCentral Sanchez, D. R., Roux, A. V. D., Michos, E. D., Blumenthal, R. S., Schreiner, P. J., Burke, G. L., & Watson, K. (2011). Comparison of the racial/ethnic prevalence of regular aspirin use for the primary prevention of coronary heart disease from the multi-ethnic study of atherosclerosis. The American Journal of Cardiology, 107(1), 41–46.CrossRefPubMedPubMedCentral
20.
go back to reference Johansen, M. E., Hefner, J. L., & Foraker, R. E. (2015). Antiplatelet and statin use in US patients with coronary artery disease categorized by race/ethnicity and gender, 2003 to 2012. The American Journal of Cardiology, 115(11), 1507–1512.CrossRefPubMed Johansen, M. E., Hefner, J. L., & Foraker, R. E. (2015). Antiplatelet and statin use in US patients with coronary artery disease categorized by race/ethnicity and gender, 2003 to 2012. The American Journal of Cardiology, 115(11), 1507–1512.CrossRefPubMed
21.
go back to reference Fang, J., George, M. G., Gindi, R. M., Hong, Y., Yang, Q., Ayala, C., et al. (2015). Use of low-dose aspirin as secondary prevention of atherosclerotic cardiovascular disease in US adults (from the National Health Interview Survey, 2012). The American Journal of Cardiology, 115(7), 895–900.CrossRefPubMedPubMedCentral Fang, J., George, M. G., Gindi, R. M., Hong, Y., Yang, Q., Ayala, C., et al. (2015). Use of low-dose aspirin as secondary prevention of atherosclerotic cardiovascular disease in US adults (from the National Health Interview Survey, 2012). The American Journal of Cardiology, 115(7), 895–900.CrossRefPubMedPubMedCentral
22.
go back to reference Winter, S. J., Sheats, J. L., & King, A. C. (2016). The use of behavior change techniques and theory in technologies for cardiovascular disease prevention and treatment in adults: A comprehensive review. Progress in Cardiovascular Diseases, 58(6), 605–612.CrossRefPubMedPubMedCentral Winter, S. J., Sheats, J. L., & King, A. C. (2016). The use of behavior change techniques and theory in technologies for cardiovascular disease prevention and treatment in adults: A comprehensive review. Progress in Cardiovascular Diseases, 58(6), 605–612.CrossRefPubMedPubMedCentral
23.
go back to reference Plotnikoff, R. C., Lubans, D. R., Costigan, S. A., & McCargar, L. (2013). A test of the theory of planned behavior to predict physical activity in an overweight/obese population sample of adolescents from Alberta, Canada. Health Education & Behavior, 40(4), 415–425.CrossRef Plotnikoff, R. C., Lubans, D. R., Costigan, S. A., & McCargar, L. (2013). A test of the theory of planned behavior to predict physical activity in an overweight/obese population sample of adolescents from Alberta, Canada. Health Education & Behavior, 40(4), 415–425.CrossRef
24.
go back to reference Norman, P., Conner, M., & Bell, R. (1999). The theory of planned behavior and smoking cessation. Health Psychology, 18(1), 89–94.CrossRefPubMed Norman, P., Conner, M., & Bell, R. (1999). The theory of planned behavior and smoking cessation. Health Psychology, 18(1), 89–94.CrossRefPubMed
25.
go back to reference Lin, C. Y., Broström, A., Nilsen, P., & Pakpour, A. H. (2018). Using extended theory of planned behavior to understand aspirin adherence in pregnant women. Pregnancy Hypertension, 12, 84–89.CrossRefPubMed Lin, C. Y., Broström, A., Nilsen, P., & Pakpour, A. H. (2018). Using extended theory of planned behavior to understand aspirin adherence in pregnant women. Pregnancy Hypertension, 12, 84–89.CrossRefPubMed
26.
go back to reference Ajzen, I. (1991). The theory of planned behavior. Organizational Behavior and Human Decision Processes, 50(2), 179–211.CrossRef Ajzen, I. (1991). The theory of planned behavior. Organizational Behavior and Human Decision Processes, 50(2), 179–211.CrossRef
27.
go back to reference Brown, D. W., Shepard, D., Giles, W. H., Greenlund, K. J., & Croft, J. B. (2005). Racial differences in the use of aspirin: An important tool for preventing heart disease and stroke. Ethnicity & Disease, 15(4), 620–626. Brown, D. W., Shepard, D., Giles, W. H., Greenlund, K. J., & Croft, J. B. (2005). Racial differences in the use of aspirin: An important tool for preventing heart disease and stroke. Ethnicity & Disease, 15(4), 620–626.
28.
go back to reference Gu, Q., Dillon, C. F., Eberhardt, M. S., Wright, J. D., & Burt, V. L. (2015). Preventive aspirin and other antiplatelet medication use among US adults aged ≥ 40 years: Data from the National Health and Nutrition Examination Survey, 2011–2012. Public Health Reports, 130(6), 643–654.CrossRefPubMedPubMedCentral Gu, Q., Dillon, C. F., Eberhardt, M. S., Wright, J. D., & Burt, V. L. (2015). Preventive aspirin and other antiplatelet medication use among US adults aged ≥ 40 years: Data from the National Health and Nutrition Examination Survey, 2011–2012. Public Health Reports, 130(6), 643–654.CrossRefPubMedPubMedCentral
29.
go back to reference Karmali, K. N., Goff, D. C., Ning, H., & Lloyd-Jones, D. M. (2014). A systematic examination of the 2013 ACC/AHA pooled cohort risk assessment tool for atherosclerotic cardiovascular disease. Journal of the American College of Cardiology, 64(10), 959–968.CrossRefPubMed Karmali, K. N., Goff, D. C., Ning, H., & Lloyd-Jones, D. M. (2014). A systematic examination of the 2013 ACC/AHA pooled cohort risk assessment tool for atherosclerotic cardiovascular disease. Journal of the American College of Cardiology, 64(10), 959–968.CrossRefPubMed
30.
go back to reference Williams, C. D., Chan, A. T., Elman, M. R., Kristensen, A. H., Miser, W. F., Pignone, M. P., et al. (2015). Aspirin use among adults in the US: Results of a national survey. American Journal of Preventive Medicine, 48(5), 501–508.CrossRefPubMed Williams, C. D., Chan, A. T., Elman, M. R., Kristensen, A. H., Miser, W. F., Pignone, M. P., et al. (2015). Aspirin use among adults in the US: Results of a national survey. American Journal of Preventive Medicine, 48(5), 501–508.CrossRefPubMed
31.
go back to reference Halbert, C. H., Armstrong, K., Gandy, O. H., & Shaker, L. (2006). Racial differences in trust in health care providers. Archives of Internal Medicine, 166(8), 896–901.CrossRefPubMed Halbert, C. H., Armstrong, K., Gandy, O. H., & Shaker, L. (2006). Racial differences in trust in health care providers. Archives of Internal Medicine, 166(8), 896–901.CrossRefPubMed
32.
go back to reference Victor, R. G., Lynch, K., Li, N., Blyler, C., Muhammad, E., Handler, J., et al. (2018). A cluster-randomized trial of blood-pressure reduction in black barbershops. New England Journal of Medicine, 378(14), 1291–1301.CrossRefPubMed Victor, R. G., Lynch, K., Li, N., Blyler, C., Muhammad, E., Handler, J., et al. (2018). A cluster-randomized trial of blood-pressure reduction in black barbershops. New England Journal of Medicine, 378(14), 1291–1301.CrossRefPubMed
33.
go back to reference Zantek, N. D., Luepker, R. V., Duval, S., Miller, K., Oldenburg, N., & Hirsch, A. T. (2014). Confirmation of reported aspirin use in community studies: Utility of serum thromboxane B2 measurement. Clinical and Applied Thrombosis/Hemostasis, 20(4), 385–392.CrossRef Zantek, N. D., Luepker, R. V., Duval, S., Miller, K., Oldenburg, N., & Hirsch, A. T. (2014). Confirmation of reported aspirin use in community studies: Utility of serum thromboxane B2 measurement. Clinical and Applied Thrombosis/Hemostasis, 20(4), 385–392.CrossRef
Metadata
Title
Aspirin Use for Cardiovascular Disease Prevention in an African American Population: Prevalence and Associations with Health Behavior Beliefs
Authors
Jeremy R. Van’t Hof
Sue Duval
Jeffrey R. Misialek
Niki C. Oldenburg
Clarence Jones
Milton Eder
Russell V. Luepker
Publication date
01-06-2019
Publisher
Springer US
Published in
Journal of Community Health / Issue 3/2019
Print ISSN: 0094-5145
Electronic ISSN: 1573-3610
DOI
https://doi.org/10.1007/s10900-019-00646-5

Other articles of this Issue 3/2019

Journal of Community Health 3/2019 Go to the issue